Miranda Lankas

The current testing rate for BRCA 1/2 mutations is currently 68% in HER2-negative early breast cancer, but eligible patients could receive better care if tested.

Watch Dr. Patrick Borgen, from Maimonides Medical Center, discuss the de-escalation of surgery during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Skipping radiation therapy for breast cancer may not affect 10-year survival, but one radiation oncologist suggests patient noncompliance with endocrine therapy is the real reason for reduced benefits.

Watch Dr. Joseph Panoff, from Miami Cancer Institute, Baptist Health South Florida, discuss radiation therapy in early stage disease during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Watch Isabel Octaviano, from Miami Cancer Institute, Baptist Health South Florida, discuss the nursing perspective to clinical trials during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Pre- and post-menopausal patients with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation are eligible to participate in the next round of Fablyn’s upcoming clinical trial.

Watch Dr. Reshma Mahtani, from Miami Cancer Institute, Baptist Health South Florida, discuss clinical trial myths during the CURE Educated Patient® Breast Cancer Summit at MBCC.

This approval is the first of its kind as a first-line systemic therapy for pediatric patients with low-grade gliomas of a specific mutation.

A recent study finds patients who test positive for an HPV biomarker may not be positive for HPV itself, and these patients see significantly lower five-year survival rates.

Patients with resectable non-small cell lung cancer treated with Imfinzi plus chemo before surgery or as monotherapy after surgery demonstrated significant improvements to event-free survival compared with those treated with neoadjuvant chemotherapy and surgery, study results show.

Patients who do not respond to immunotherapy have reduced CD5 activity in their tumors, opening the door for more effective immunotherapy treatments.

Bladder cancer survivors face a bevy of challenges post-treatment, but an immediately available service strives to ease the burden.

How do survivors of head and neck cancer cope with drastic changes to one of the most visibly identifiable body parts — the head?

Over a quarter of adolescent or young adult patients diagnosed with sarcomas will have difficulties financially, romantically for an extended period after diagnosis.

Vaccines have been a hot-button issue for several years now, but are cancer survivors putting their health at risk by avoiding the HPV vaccine?

Oncologists suggest that treatment decisions made for transgender cancer patients should not be made through the lens of their gender identity but should encourage physicians to discuss a wider variety of treatment options with all patients.

A combination of the blood pressure medication, Cozaar, to a chemo regimen is more effective in reducing genes related to immunosuppression and invasion than chemo alone, study results show.

An expert discusses the value of Jaypirca’s recent accelerated FDA approval for relapsed/refractory mantle cell lymphoma, as well as where treatment may go next.

After receiving supportive care during her college cancer journey, this survivor now works to guide other patients through their treatments.

Patients treated with Nubeqa were less likely to develop disease metastasis or discontinue treatment 6 to 18 months after ARI course start compared to Xtandi or Erleada, according to data presented at ASCO GU.

Postmenopausal women cancer survivors, including lung, breast, colorectal and endometrial cancer, may have a greater physical function decline than is generally expected at their age, which may lead to lower quality of life after treatment.

An expert on urological side effects of cancer treatments most often associated with prostate cancer discusses options, even for those decades past initial treatment.

When comparing mindfulness activities with physical exercise and no exercise to treat cancer-related cognitive impairment, breast cancer survivors showed similar outcomes across the board, leading researchers to suggest acknowledging the side effect may help patients cope.

A retired psychotherapist and social worker published a memoir detailing his experiences with disease and navigating the health care space, as well as “all the things that people think about (but) they don't necessarily talk about or even talk to their doctors about.”

Treatments before surgery for rectal adenocarcinoma, a type of rectal cancer, have increased and correlated with preservative surgeries and improved overall survival in the last 16 years, though improvements may still be needed for disease screening, an expert said.

Exercising moderately every week has been linked to improved disease outcomes at any BMI in patients with colorectal cancer.

Data demonstrate that iberdomide alone or in combination with other treatments may be a promising option for patients with relapsed/refractory lymphoma.

Imfinzi alone or combined with Imjudo may improve survival and tumor response when administered before surgery, opening the door to neoadjuvant mesothelioma treatments.

"We call ourselves the wolf pack. ... It is kind of tongue in cheek, but there is some seriousness behind how we view each other in terms of having each other’s backs,” said Trevor Maxwell, a stage 4 colon cancer survivor and the founder of Man Up to Cancer.